Zimmer Biomet (NYSE:ZBH) Shares Down 8.8% – Here’s What Happened

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) shares traded down 8.8% during trading on Tuesday . The company traded as low as $83.94 and last traded at $84.4710. 2,701,336 shares traded hands during mid-day trading, an increase of 25% from the average session volume of 2,167,881 shares. The stock had previously closed at $92.59.

Zimmer Biomet News Roundup

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Q1 beat on both EPS (adjusted $2.09 vs. ~$1.86 est.) and revenue (~$2.09B vs. ~$2.06B); revenue grew ~9.3% year?over?year with margin expansion noted. PR Newswire Q1 Results
• Positive Sentiment: Management raised FY?2026 adjusted EPS guidance to $8.40–$8.55 (above the prior consensus ~8.39) and reiterated revenue guidance of ~$8.4–$8.6B, signaling confidence in demand and new product uptake. Reuters: Guidance Raise & CFO Departure
• Positive Sentiment: Company cited strong device demand and new product launches as drivers of outperformance and margin improvement this quarter. Earnings Call Transcript
• Neutral Sentiment: Underlying organic growth was modest on an organic constant?currency basis (reported 9.3%, organic CC ~2.9%), suggesting some of the beat was mix? and currency?related rather than broad-based acceleration. PR Newswire Q1 Results
• Negative Sentiment: Leadership turnover: CFO Suketu Upadhyay is departing immediately and Paul Stellato is named interim CFO; some outlets also reported a CEO exit, which heightens short?term governance and execution uncertainty. PR Newswire CFO Transition MSN: CEO Exit Report
• Negative Sentiment: Despite the beat, shares slipped (including an early dip in pre?market trading) — suggesting investors focused on execution risks (salesforce shifts noted in previews) and the management changes rather than the headline beat. Zacks: Premarket Dip

Analyst Ratings Changes

ZBH has been the subject of a number of research analyst reports. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a report on Monday, January 26th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their price target for the stock from $94.00 to $120.00 in a report on Monday, January 5th. BTIG Research restated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, April 7th. Finally, Leerink Partners began coverage on Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $105.95.

Zimmer Biomet Price Performance

The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The company’s fifty day moving average price is $93.52 and its 200 day moving average price is $92.98. The company has a market capitalization of $16.06 billion, a P/E ratio of 23.43, a PEG ratio of 1.87 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.09 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same period in the previous year, the company posted $1.81 earnings per share. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.39 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is 27.12%.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.28% of the stock is owned by corporate insiders.

Institutional Trading of Zimmer Biomet

Several large investors have recently made changes to their positions in the company. DV Equities LLC acquired a new position in Zimmer Biomet during the fourth quarter valued at approximately $25,000. Key Financial Inc boosted its holdings in shares of Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. increased its stake in shares of Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Monetary Solutions Ltd acquired a new position in shares of Zimmer Biomet during the 4th quarter worth $30,000. Finally, Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth $31,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.